Table 1 Clinical characteristics of study participants
From: Toxicity of insulin-derived amyloidosis: a case report
Case no. | Age (y) | Sex | Insulin duration (y) | Insulin preparation | Insulin dose (U/d) |
|---|---|---|---|---|---|
1 | 62 | Male | 20 | Lispro + Glargine | 116 |
2 | 82 | Female | 12 | Lispro + Glargine | 30 |
3 | 71 | Male | 25 | Lispro + Glargine | 47 |
4 | 68 | Male | 18 | Lispro + Glargine | 33 |
5 | 58 | Male | 15 | Lispro + Glargine | 52 |